<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116037</url>
  </required_header>
  <id_info>
    <org_study_id>S2008 Rev. D</org_study_id>
    <nct_id>NCT01116037</nct_id>
  </id_info>
  <brief_title>ATS 3f(r) Aortic Bioprosthesis Model 1000 Post Approval Study</brief_title>
  <acronym>PAS</acronym>
  <official_title>ATS 3f(r) Aortic Bioprosthesis Model 1000 Post Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to determine if there is an increased incidence and
      rate of aortic regurgitation in younger (&lt;/= 70 years of age) patients implanted with the
      Model 1000 and undergoing isolated aortic valve replacement of his/her native aortic valve,
      or replacement of a failed prosthesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center non-randomized trial designed to obtain 606 patient years. Each enrolled
      patient will be followed for a minimum of six (6) years. Preoperative, discharge or 30 days
      (whichever comes last), 3-6 month, and annual follow-up data are required.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision to end study due to limited enrollment and study population
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Goal is to Assess the Freedom From Clinically Significant (Moderate or Greater) Aortic Regurgitation for the Patients Implanted With 3f Aortic Bioprothesis, Model 1000</measure>
    <time_frame>Six Years</time_frame>
    <description>Freedom from clinically significant (moderate or greater) aortic regurgitation will be determined through echocardiography and compared against the freedom from regurgitation event rates from the previous IDE study, G010284 used for PMA approval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Analysis Will be Based on the Occurence of Cardiovascular Complications.</measure>
    <time_frame>Six Years</time_frame>
    <description>Safety Analysis will be based on the the number of participants with cardiovascular complications.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Heart Valve Diseases</condition>
  <arm_group>
    <arm_group_label>ATS 3f Aortic Bioprosthesis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ATS 3f Aortic Bioprosthesis</intervention_name>
    <description>Equine Pericardial Bioprosthesis for replacement of diseased valve</description>
    <arm_group_label>ATS 3f Aortic Bioprosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is &lt;/= 70 years of age and requires isolated aortic valve replacement with or
             without concomitant procedures such as coronary artery bypass or another valve
             reconstruction. (The three remaining valves must be of native tissue).

          -  Patient is sufficiently ill to warrant replacement of his/her diseased natural or
             prosthetic valve (excluding the ATS 3f Aortic Bioprosthesis, Model 1000
             bioprosthesis), based on standard cardiovascular diagnostic workups.

          -  Patient is in satisfactory condition, based on the physical exam and Investigator's
             experience, to be an average or better operative risk, (i.e., likely to survive three
             years postoperatively).

          -  Patient is geographically stable and willing to return to the implant center for
             follow-up visits.

          -  Patient has been adequately informed and consents to his/her participation in the
             clinical study, and of what will be required of him/her, in order to comply with the
             protocol.

        Exclusion Criteria:

          -  Patient is older than seventy (70) years of age.

          -  Patient has a non-cardiac major or progressive disease, which in the Investigator's
             experience produces an unacceptable increased risk to the patient, or results in a
             life expectancy of less than 3 years.

          -  Patient is an intravenous drug and/or alcohol abuser.

          -  Female patient is pregnant (urine HCG test result positive), or lactating.

          -  Patient presents with active endocarditis.

          -  Patient presents with congenital bicuspid aortic anatomy.

          -  This patient presents with abnormal aortic root geometry.

          -  Patient has chronic renal failure or is on renal dialysis.

          -  Patient has a previously implanted prosthetic valve that is not being replaced by a
             study valve.

          -  Patient requires mitral, tricuspid or pulmonic valve replacement.

          -  Patient presents with dilatation of the ascending aorta, Marfan Syndrome,
             Ehlers-Danlos syndrome, cystic medial degeneration, or other condition causing the
             ascending aorta to be irregular in geometry or physiology as seen via preoperative
             imaging.

          -  Patient is participating in concomitant research studies of investigational products.

          -  Patient will not agree to return to the implant center for the required number of
             follow-up visits or is geographically unavailable for follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Palmer</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiac Surgery Clinical Research Center, Inc.</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Main Line Health Heart Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.medtronic.com</url>
    <description>Medtronic Corporate Website</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <results_first_submitted>October 17, 2016</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2017</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diseased Heart Valve, Replacement, Aortic, Stentless</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ATS 3f Aortic Bioprosthesis</title>
          <description>ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
ATS 3f Aortic Bioprosthesis: Equine Pericardial Bioprosthesis for replacement of diseased valve</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ATS 3f Aortic Bioprosthesis</title>
          <description>ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
ATS 3f Aortic Bioprosthesis: Equine Pericardial Bioprosthesis for replacement of diseased valve</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Recruiting sites included 4 in the US (n=9) and 1 in Canada (n=17)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Goal is to Assess the Freedom From Clinically Significant (Moderate or Greater) Aortic Regurgitation for the Patients Implanted With 3f Aortic Bioprothesis, Model 1000</title>
        <description>Freedom from clinically significant (moderate or greater) aortic regurgitation will be determined through echocardiography and compared against the freedom from regurgitation event rates from the previous IDE study, G010284 used for PMA approval.</description>
        <time_frame>Six Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ATS 3f Aortic Bioprosthesis</title>
            <description>ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
ATS 3f Aortic Bioprosthesis: Equine Pericardial Bioprosthesis for replacement of diseased valve</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Goal is to Assess the Freedom From Clinically Significant (Moderate or Greater) Aortic Regurgitation for the Patients Implanted With 3f Aortic Bioprothesis, Model 1000</title>
          <description>Freedom from clinically significant (moderate or greater) aortic regurgitation will be determined through echocardiography and compared against the freedom from regurgitation event rates from the previous IDE study, G010284 used for PMA approval.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Analysis Will be Based on the Occurence of Cardiovascular Complications.</title>
        <description>Safety Analysis will be based on the the number of participants with cardiovascular complications.</description>
        <time_frame>Six Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ATS 3f Aortic Bioprosthesis</title>
            <description>ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
ATS 3f Aortic Bioprosthesis: Equine Pericardial Bioprosthesis for replacement of diseased valve</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Analysis Will be Based on the Occurence of Cardiovascular Complications.</title>
          <description>Safety Analysis will be based on the the number of participants with cardiovascular complications.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ATS 3f Aortic Bioprosthesis</title>
          <description>ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
ATS 3f Aortic Bioprosthesis: Equine Pericardial Bioprosthesis for replacement of diseased valve</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Serious</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular Complications</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Serious</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Valve Dysfunction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan Palmer</name_or_title>
      <organization>Medtronic</organization>
      <phone>+17635149732</phone>
      <email>ryan.j.palmer@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

